Sign up online today & collaborate
or click here to find out more
Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company.
Lotta Ljungqvist has a broad range of commercial and directorial experience. She currently holds a dual role as President and CEO of GE Nordics, responsible for GE’s growth in all sectors across the region. She is also CEO of BioProcess Innovation Hub, a government initiative, where she has been setting up a new facility aiming to support biotechnology companies in Scandinavia.
Before taking on the dual role at GE Nordics she spent eight years with GE Healthcare Life Sciences as its Global Head of R&D BioProcess. During this time, the division doubled in size due to a series of acquisitions.
Prior to this, Lotta was CEO of a start-up Biotech, IMED AB, based on research from the Karolinska Institute. She also worked at Biovitrum AB for six years, as SVP, Biopharmaceutical Process Development, selling cell culture, purification and analytical services to the biopharmaceutical sector.
Lotta has held several board positions including her current position as Non-Executive Director on the board of Atlas Antibodies, a privately held manufacturer and distributor of research antibodies and as Board Director of Vinnova, the Swedish government agency that administers state funding for research and development.
Dr Ken Cunningham, Abzena’s Chairman, said:
“Lotta has a deep understanding of biomanufacturing and development services, and how to support the needs of biopharmaceutical companies. As a result of her strategic and operational capability, to manage a contract development and manufacturing service business, she will be an invaluable asset to Abzena, as it aims to deliver value-adding services and technology solutions to its customers.”